Loading
Life sciences · Journal article
Anaerobe · August 1, 2026
A consensus or society position rather than new primary data.
This is a conceptual perspective piece introducing 'Microbiome Stewardship' as a framework for clinical and drug-development decision-making, arguing that antimicrobial use should be evaluated and limited to preserve gut microbiome structure and function. The source presents no original empirical evidence, trial data, or comparative outcomes to support specific clinical recommendations.
Journal article.
Antimicrobial use has the most disruptive effect on the microbiome, altering structure and function and promoting antimicrobial resistant gene generation Proposed strategies include consideration of antimicrobial administration route and selective rather than routine empiric anaerobic coverage Microbiome evaluation should become standard in antimicrobial drug development and clinical decision-making processes
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
Clinicians should consider this a call to integrate microbiome preservation into prescribing decisions and to question routine empiric broad-spectrum or anaerobic coverage; however, the source provides no quantified comparative outcomes or evidence hierarchy to guide specific changes to practice.
A conceptual framework and expert recommendation proposing microbiome stewardship as a clinical and policy principle, without empirical trial data or regulatory action.
Clinicians should consider this a call to integrate microbiome preservation into prescribing decisions and to question routine empiric broad-spectrum or anaerobic coverage; however, the source provides no quantified comparative outcomes or evidence hierarchy to guide specific changes to practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Healthy human gut microbiomes are essential for overall wellness and must be safeguarded by incorporating preservation into clinical decision-making processes and policies. Given the paradigm shift of single-acting bacteria causing infectious diseases to a new understanding of interacting communities of bacteria that build up stable network structures and functions to prevent diseases, a One-Health umbrella has emerged that interconnects all life through their respective microbiota. The preservation of this homeostasis is a term coined Microbiome Stewardship. Although multi-causal, antimicrobial use has the most disruptive effect on the microbiome, quickly changing microbiome structure and function as well as promoting antimicrobial resistant gene (ARG) generation and abundance. Clinically, Microbiome Stewardship could lead to new strategies around antimicrobial administration route and enhanced consideration of whether anaerobic coverage is required, especially routine empiric coverage. Antimicrobial resistance (AMR) and perturbation of the microbiome effect short- and long-term patient outcomes and should drive the drug development process and repurposing of current antimicrobials. In the new scientific era of systems biology providing increasingly accessible and cost-effective studies, evaluation of the microbiome during the antimicrobial drug development process should become the new standard. Microbiome Stewardship incorporation into clinical practice and drug development will advance patient outcomes and AMR prevention on an individual and public health platform.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.